Pricing & Market Access Briefing

To develop and execute successful market access strategies for a product pipeline and on-market products, you must stay fully informed about ongoing developments in global healthcare systems and relevant pricing policies.

Our monthly Pricing & Market Access Briefings provide insights, information, and analysis on:

  • Payer trends, and drivers of market access success
  • Pricing policy and regulations in key markets
  • Regulatory agency requirements and policies that govern market approval, and the impact on reimbursement decisions

Current Issue – November 2017

The Rise of Value-Based Contracting for Biopharmaceuticals and Medical Technologies

Economic forces are forging a new payer environment with value demonstration at its core, and the threshold for evidence on new biopharmaceuticals and medical technologies is higher than ever. In response, pharma, biotech, and med device companies are developing new, increasingly more complex go-to-market strategies that include taking greater ownership of the patient pathway, developing beyond-the-pill solutions, proposing novel pricing schemes, and integrating, value-based market access approaches.

Subscribe today to learn more about how:

  • The focus of payer contracts is shifting away from solely net cost to value-based inclusion of appropriate utilization, performance-based risk sharing and health outcomes-related elements
  • Payers are motivated to enter VBCs due to performance and financial uncertainty, inadequate data, and a price/value mismatch
  • Selecting the best VBC is a complex process requiring market analysis, financial modeling and strategic planning

Contracting will continue to evolve with pricing pressure, robust information and advanced analytics as catalysts for value element integration. 

Examples of Past Issues

Thank you for taking an interest in our monthly briefings. Please subscribe to ensure you automatically receive all future issues by email.

Briefing thumbnailP&MA Briefing September 2016: The Price of Uncertainty: When Conditional Marketing Authorisation Leads to Payer Rejection Download P&MA Briefing

Briefing thumbnailP&MA Briefing July & August 2016: The Impact of Brexit on Pricing and Market Access Download P&MA Briefing

Briefing thumbnailP&MA Briefing June 2016: The Funding Conundrum of High Cost Gene and Cell Therapies Download P&MA Briefing